Skip to content

Clinical Observation of Xiakucao Oral Liquid in Treating Graves Disease

Clinical Observation of Xiakucao Oral Liquid in Treating Graves Disease

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042129
Enrollment
Unknown
Registered
2021-01-14
Start date
2021-01-14
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves Disease

Interventions

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 65 years; 2. According to the diagnostic criteria of Graves disease who diagnosed with Graves disease and with goiter; 3. Who have signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with thyrotoxicosis caused by causes other than Graves' disease, such as nodular toxic goiter and autonomous high-functioning thyroid adenoma; 2. Patients with active thyroid eye disease; 3. Patients with thyroid cancer and other malignant tumors; 4. Patients with abnormal liver and kidney function (ALT or AST > 2 times the upper limit of normal, Scr > upper limit of normal) and other serious diseases of the system; 5. Patients with a history of radioactive 131I or surgical treatment; 6. Women with pregnancy or lactation; 7. Have used antithyroid drugs or other drugs that may affect this test in the past two weeks; 8. Patients with hyperthyroidism crisis or hyperthyroidism with myasthenia gravis; 9. Those who are known to be allergic to the test drug or its components; 10. Researchers consider that they are not suitable for selection.

Design outcomes

Primary

MeasureTime frame
FT3;TSH;FT4;Alb;PA;

Secondary

MeasureTime frame
Goiter scale;TRAb;TGAb;TPOAb;

Countries

China

Contacts

Public ContactWei Jun-Ping

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

weijunping@126.com+86 10-88001245

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026